Prime Therapeutics announces formulary recommendations for adalimumab biosimilars to AbbVie’s Humira®

Jul 12, 2023

Prime Therapeutics announced its 2023 recommendations for formularies that include AbbVie’s Humira® (adalimumab).  The pharmacy benefit manager will recommend coverage of the following adalimumab biosimilars to commercial clients: 

  • Amgen’s Amjevita® (low concentration) and Boehringer Ingelheim’s Cyltezo® (interchangeable low concentration); or 
  • Amgen’s Amjevita® (low concentration) and Samsung Bioepis/Organon’s Hadlima® (high and low concentration). 

Prime is also recommending coverage of Cyltezo® for Medicare Part D formularies.  On 10 July 2023, Cigna Health announced its preferred adalimumab biosimilars.  

Print Page Mail Article